Objectives: To test CIDP patients for IgG positivity towards NF155, and NF140.
Samples: 23-55
| SAMPLE | NF155 | NF140 |
|---|---|---|
| 23 | - | - |
| 24 | - | - |
| 25 | - | - |
| 26 | - | - |
| 27 | - | - |
| 28 | - | - |
| 29 | + | + |
| 30 | - | - |
| 31 | - | - |
| 32 | - | - |
| 33 | - | - |
| 34 | - | - |
| 35 | - | - |
| 36 | - | - |
| 37 | - | - |
| 38 | - | - |
| 39 | - | - |
| 40 | - | - |
| 41 | - | - |
| 42 | - | - |
| 43 | - | - |
| 44 | - | - |
| 45 | - | - |
| CONTROL- | - | - |
| CONTROL+ (LAC-NF155) | + | - |
NF155, NF140 ICC:
- HEKs 293 Cells Transfection: 2018.07.26
- Blocking solution: 5% goat serum in PBS.
- Patient’s sera diluted 1/100 for IgG with 5% goat serum in PBS.
- Primary antibody: AF3235 diluted 1/1000.
- Secondary antibodies:
- For IgG: GAC 488 (1/1000) + GAH 594 IgG (1/1000)
- Vectashield mounting medium.
Results: Sample 29 was positive for IgG towards NF155 and NF140. The rest of samples were negative. We have to repeat sample 26 for NF 140 and sample 45 for NF 155 because there were not enough transfected cells.
